Short Communication: PDF OnlyFotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot studyBröcker, E -B1; Bohndorf, W2; Kämpgen, E1; Trcka, J1; Messer, P2; Tilgen, W3; Engenhart, K4; Flentje, M2Author Information 1Department of Dermatology, University of Wurzburg, Josef-Schneider-Strasse 2, D-97080 Würzburg, Germany. Fax. (+49) 931 201 3362 2Department of Radiotherapy, University of Würzburg, Germany 3Departments of Dermatology, University of Heidelberg, Germany 4Departments of Radiotherapy, University of Heidelberg, Germany Melanoma Research: October 1996 - Volume 6 - Issue 5 - p 399-401 Buy Abstract Melanoma patients with multiple brain metastases not amenable to surgery or stereotactic radiotherapy were treated with total brain irradiation in fractions of 2.5 Gy four times weekly, up to 40 Gy. At days 1, 8, and 25 100 mg/m2 fotemustine was infused 4 h before Irradiation. Of 12 evaluable patients, four showed partial remission and three stabilization in the brain. The median survival in these two groups of patients was 6 months; the survival of the other patients was 2 months. Severe haematological side effects were observed in 6/13 patients. In conclusion, the combination of fotemustine and total brain Irradiation seems to be more effective than either treatment alone, but bears the risk of additional bone-marrow toxicity. © Lippincott-Raven Publishers.